全反式维甲酸治疗缓解后急性早幼粒细胞白血病的骨髓移植治疗

BMT IN THE TREATMENT OF PATIENTS WITH AML M 3 AFTER COMPLETE REMISSION BY ALL TRANS RETINOIC ACID

１６例经全反式维甲酸治疗达完全缓解后进行了骨髓移植治疗的急性早幼粒细胞性白血病，其中８例为异基因骨髓移植，８例为自体骨髓移植。８例Ａｌｏ－ＢＭＴ的６例存活（５３＋、５２＋、１５＋、１０＋、７＋及３＋月），２例病人死于急性移植物抗宿主病（１＋月及２＋月）。８例ＡＢＭＴ病人有６例存活（５９＋、４５＋、４０＋、３５＋、３２＋及２９＋月），１例病人复发（２３＋月），另１例移植早期死亡（１＋）月。

Sixteen patients with acute myeloid leukemia M3(AML M 3) in first complete remission after treatment of all trans retinoic acid were treated by Allo BMT(n=8) and ABMT(n=8). After Allo BMT, six patients are alive(53 +,52 +,15 +,10 +,7 + and 3 + months, respectively), two patients died of GVHD(1 +and 2 + months). In ABMT, six patients are alive(59 +,45 +,40 +,35 +,32 + and 29 + months respectively), one patient relapsed and died (23 + months), another died early (1 month). We concluded that Allo BMT and ABMT are effective in treating patients with AML M 3 after the first complete remission with all trans retinoic acid.